Evidence map›Paper›PMID 38979183›Full record

ArticlebioRxiv : the preprint server for biology2024

Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer.

Remziye E Wessel, Nardin Ageeb, Joseph M Obeid, Ileana Mauldin, Kate A Goundry, Gabriel F Hanson, Mahdin Hossain, Chad Lehman, Ryan D Gentzler, Nolan A Wages and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Remziye E WesselDepartment of Biomedical Engineering, University of Virginia (UVA) School of Medicine, Charlottesville, Virginia 22908.ORCID 0000-0002-8596-4700
Nardin AgeebDepartment of Biology, UVA, Charlottesville, Virginia 22908.
Joseph M ObeidDepartment of Thoracic Surgery, Temple University Hospital, Philadelphia, Pennsylvania 19140.ORCID 0000-0002-6111-9289
Ileana MauldinDepartment of Surgery, UVA School of Medicine, Charlottesville, Virginia 22908.ORCID 0000-0002-9318-8342
Kate A GoundryDepartment of Biomedical Engineering, University of Virginia (UVA) School of Medicine, Charlottesville, Virginia 22908.
Gabriel F HansonDepartment of Biomedical Engineering, University of Virginia (UVA) School of Medicine, Charlottesville, Virginia 22908.ORCID 0009-0003-0202-062X
Mahdin HossainBeirne B. Carter Center for Immunology Research, UVA School of Medicine, Charlottesville, Virginia 22908.
Chad LehmanBeirne B. Carter Center for Immunology Research, UVA School of Medicine, Charlottesville, Virginia 22908.
Ryan D GentzlerDepartment of Medicine, Hematology and Oncology, UVA School of Medicine, Charlottesville, Virginia 22908.ORCID 0000-0002-8983-6677
Nolan A WagesDepartment of Biostatistics, Virginia Commonwealth University, Richmond, Virginia 23298-0032.
Craig L SlingluffDepartment of Surgery, UVA School of Medicine, Charlottesville, Virginia 22908.ORCID 0000-0002-6664-4373
Timothy N J BullockBeirne B. Carter Center for Immunology Research, UVA School of Medicine, Charlottesville, Virginia 22908.ORCID 0000-0001-6141-3261
Sepideh DolatshahiDepartment of Biomedical Engineering, University of Virginia (UVA) School of Medicine, Charlottesville, Virginia 22908.ORCID 0000-0003-0226-0933
Michael G BrownBeirne B. Carter Center for Immunology Research, UVA School of Medicine, Charlottesville, Virginia 22908.ORCID 0000-0003-2872-7685

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Dina Gould Halme · 1987 to 2026
$72.1M
Postdoctoral Training Grant for MDs in Surgical Oncology ResearchT32CA163177 · NCI · UNIVERSITY OF VIRGINIA · PI Craig Lee Slingluff, Allan Tsung · 2011 to 2026
$4.6M
Interdisciplinary Training in Systems & Biomolecular Data ScienceT32GM145443 · NIGMS · UNIVERSITY OF VIRGINIA · PI Kevin A Janes, Jason Papin · 2022 to 2026
$1.5M
NCI NIH HHS P30 CA044579NCI NIH HHS T32 CA163177NIGMS NIH HHS T32 GM145443
6 · The paper itself

Abstract

Background: MHC class I (MHC-I) loss is frequent in non-small cell lung cancer (NSCLC) rendering tumor cells resistant to T cell lysis. NK cells kill MHC-I-deficient tumor cells, and although previous work indicated their presence at NSCLC margins, they were functionally impaired. Within, we evaluated whether NK cell and CD8 T cell infiltration and activation vary with MHC-I expression. Methods: We used single-stain immunohistochemistry (IHC) and Kaplan-Meier analysis to test the effect of NK cell and CD8 T cell infiltration on overall and disease-free survival. To delineate immune covariates of MHC-I-disparate lung cancers, we used multiplexed immunofluorescence (mIF) imaging followed by multivariate statistical modeling. To identify differences in infiltration and intercellular communication between IFNγ-activated and non-activated lymphocytes, we developed a computational pipeline to enumerate single cell neighborhoods from mIF images followed by multivariate discriminant analysis. Results: Spatial quantitation of tumor cell MHC-I expression revealed intra- and inter-tumoral heterogeneity, which was associated with the local lymphocyte landscape. IHC analysis revealed that high CD56 Conclusions: Tumor-infiltrating NK cells and CD8 T cells jointly affected control of NSCLC tumor progression. Co-association of NK and CD8 T cells was most evident in MHC-I-bearing tumors, especially in the presence of IFNγ. Frequent co-localization of IFNγ

Indexed as

CD8 T cellscell co-localizationinterferon-gammaintratumor heterogeneityMHC class Imultiplex immunofluorescencenatural killer cellspatient survivalspatial analysissystems immunologytissue micro-arraytumor-infiltrating lymphocytes

Identifiers

PMID38979183
PMCPMC11230195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.